HIV Infections Clinical Trial
Official title:
Anal HPV Infection and Abnormal Cytology in HIV-infected Women
The population of HIV infected women seen at Boston Medical Center may have a higher frequency of anal cytologic and histologic abnormalities than what is reported for the non-HIV infected population.
BACKROUND FOR THIS STUDY Anal cancer is a growing problem in the US. The incidence of anal
cancer has increased among both men (160%) and women (78%) from 1973 to 2000 in the US [1].
In HIV-infected men the incidence of SCCA (squamous cell cancer of the anus) was found to
range from 49-92 per 100,000 patient years [2]. This prompted recommendations on screening
for anal cancer in this population. HIV-infected women are also at increased risk for
developing anal cancer. A study based on data from AIDS and cancer registries found that the
risk of anal cancer among women in the general population is about 1.2% and it increases up
to 3.9% in the HIV-infected women. In addition, HIV-infected women had eight times the risk
of in situ anal cancer compared with the number of expected cases [3].
SCCA appears to have many similarities to cervical cancers. HPV has been detected in 88% of
anal cancer specimens with HPV-16 found in 73% of SCCA and HPV-18 in 7% [1]. In addition,
SCCA develops in the transformation zone between the squamous epithelium of the anus and the
columnar epithelium of the rectum, is frequently associated with dysplasia of the anus and
may be preceded by squamous intraepithelial changes which are also associated with HPV.
Cervical cytology, also known as pap smear, can detect cervical cancer and its precursors.
Countries who have adopted cervical cancer screening programs have had dramatic decreases in
both the morbidity and mortality rates of cervical cancer.
Anal cytology may also be used to screen for HPV associated anal lesions, and among
HIV-infected men who have sex with men, an abnormal cytology is frequently associated with a
dysplastic squamous cell lesion of the anus. Anal HPV infections (high risk types) have been
found in 53 ¿ 95% of HIV-infected men. Abnormal anal cytology has been found in 41-81% of
HIV-infected men screened with high-grade cytologic findings in 2-25% of these patients [2].
There have been only a few studies looking at anal cytology in HIV-infected women. The
largest study (n=235), by Holly and Palefsky [4], found that HIV positive women had a 26%
prevalence of anal cytologic abnormalities (mostly atypical squamous cells of undetermined
significance [ASCUS] and low grade squamous intraepithelial lesions [LSIL]). Forty-six of
these women with abnormal cytology (60) underwent high resolution anoscopy (HRA) and 14 were
found to have biopsy proven HSIL.
Several risk factors for anal cytologic abnormalities in women have been suggested, such as
positive anal HPV test, history of anal intercourse, history of cervical squamous
intraepithelial lesions (SIL), history of vulvar warts, multifocal cervical SIL, history of
sexually transmitted infections, more than 10 sexual partners, history of cervical, vulvar
or vaginal cancer, immunosuppression after solid organ transplantation, HIV infection,
long-term corticosteroids use and cigarette smoking.
It has been suggested that all HIV-infected women, women with cervical cancer and women with
high-grade vulvar disease or cancer should be screened for anal cytologic abnormalities.
However, as described above there is very scanty literature describing the prevalence and
incidence in this patient population and the largest study was conducted prior to the HAART
era.
We plan to estimate the prevalence and 6-12 month incidence of abnormal anal cytology with
histologic correlates in the HIV-infected women seen at BMC. We hope that the information
will allow us to make screening recommendations for this patient population.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |